Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT06343402




Registration number
NCT06343402
Ethics application status
Date submitted
22/03/2024
Date registered
2/04/2024
Date last updated
30/10/2024

Titles & IDs
Public title
Study of BBO-8520 in Adult Subjects with KRASG12C Non-small Cell Lung and Colorectal Cancer
Scientific title
A Phase 1a/1b Open-Label Study of BBO-8520 As Monotherapy and As Part of Combination Therapy in Subjects with Advanced KRASG12C Mutant Non-Small Cell Lung Cancer and Colorectal Cancer - the ONKORAS-101 Study
Secondary ID [1] 0 0
ONKORAS-101
Secondary ID [2] 0 0
TBBO8520-101
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Non-small Cell Lung Cancer 0 0
Metastatic Non-Small Cell Lung Cancer 0 0
NSCLC 0 0
KRAS G12C 0 0
Metastatic Lung Cancer 0 0
Advanced Lung Carcinoma 0 0
Colorectal Cancer 0 0
Metastatic Colorectal Cancer 0 0
CRC 0 0
Advanced Colorectal Carcinoma 0 0
Metastatic Colon Cancer 0 0
Colon Cancer 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Lung - Mesothelioma
Cancer 0 0 0 0
Lung - Non small cell
Cancer 0 0 0 0
Lung - Small cell
Cancer 0 0 0 0
Bowel - Back passage (rectum) or large bowel (colon)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - BBO-8520
Treatment: Drugs - Pembrolizumab

Experimental: Cohort 1a - Dose Escalation/Dose Finding Monotherapy - Participants enrolled in this cohort will receive BBO-8520 (different dose levels will be evaluated) once a day (QD) as monotherapy

Experimental: Cohort 1b - Dose Escalation/Dose Finding Combination Therapy - Participants enrolled in this cohort will receive BBO-8520 (different dose levels will be evaluated) once a day (QD) in combination with pembrolizumab infusion (IV)

Experimental: Cohort 2a - Dose Expansion Monotherapy - Participants enrolled in this cohort will receive BBO-8520 once a day (QD) as monotherapy

Experimental: Cohort 2b - Dose Expansion Combination Therapy - Participants enrolled in this cohort will receive BBO-8520 once a day (QD) in combination with pembrolizumab infusion (IV)


Treatment: Drugs: BBO-8520
Participants will receive assigned dose of BBO-8520 orally (PO), QD

Treatment: Drugs: Pembrolizumab
Patients will receive IV pembrolizumab
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Adverse Events
Timepoint [1] 0 0
approximately 3 years
Primary outcome [2] 0 0
Dose-limiting toxicities (DLTs)
Timepoint [2] 0 0
approximately 3 years
Secondary outcome [1] 0 0
To evaluate preliminary antitumor activity of BBO-8520
Timepoint [1] 0 0
approximately 3 years
Secondary outcome [2] 0 0
To evaluate preliminary antitumor activity of BBO-8520
Timepoint [2] 0 0
approximately 3 years
Secondary outcome [3] 0 0
Overall Survival (OS)
Timepoint [3] 0 0
approximately 3 years
Secondary outcome [4] 0 0
To characterize the pharmacokinetics (PK) of BBO-8520
Timepoint [4] 0 0
approximately 3 years
Secondary outcome [5] 0 0
To characterize the pharmacokinetics (PK) of BBO-8520
Timepoint [5] 0 0
approximately 3 years
Secondary outcome [6] 0 0
To characterize the pharmacokinetics (PK) of BBO-8520
Timepoint [6] 0 0
approximately 3 years
Secondary outcome [7] 0 0
To characterize the pharmacokinetics (PK) of BBO-8520
Timepoint [7] 0 0
approximately 3 years

Eligibility
Key inclusion criteria
* Histologically documented locally advanced or metastatic non-small cell lung cancer or colorectal cancer with a KRAS G12C mutation
* Measurable disease by RECIST v1.1
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-1
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Patients with malignancy within the last 2 years as specified in the protocol
* Patients with untreated brain metastases
* Patients with known hypersensitivity to BBO-8520 or its excipients
* For Cohorts 2a and 2b:
* Patients with a known hypersensitivity to pembrolizumab or its excipients
* Patients with active autoimmune disease of history of autoimmune disease that might recur
* Patients with a history of interstitial lung disease/pneumonitis that required steroids, or current interstitial lung disease/pneumonitis

Other inclusion/exclusion criteria may apply

Study design
Purpose of the study
Treatment
Allocation to intervention
Non-randomised trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Other
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
22/05/2024
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/02/2028
Actual
Sample size
Target
229
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Kinghorn Cancer Centre - Darlinghurst
Recruitment hospital [2] 0 0
Flinders Medical Centre - Bedford Park
Recruitment hospital [3] 0 0
The Queen Elizabeth Hospital - Woodville South
Recruitment hospital [4] 0 0
Peninsula & South Eastern Hematology and Oncology Group (PAS) - Frankston
Recruitment hospital [5] 0 0
Peter MacCallum Cancer Centre - Melbourne
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
5042 - Bedford Park
Recruitment postcode(s) [3] 0 0
5011 - Woodville South
Recruitment postcode(s) [4] 0 0
3199 - Frankston
Recruitment postcode(s) [5] 0 0
3051 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Connecticut
Country [3] 0 0
United States of America
State/province [3] 0 0
Kansas
Country [4] 0 0
United States of America
State/province [4] 0 0
Ohio
Country [5] 0 0
United States of America
State/province [5] 0 0
Tennessee
Country [6] 0 0
United States of America
State/province [6] 0 0
Utah
Country [7] 0 0
United States of America
State/province [7] 0 0
Virginia
Country [8] 0 0
United States of America
State/province [8] 0 0
Washington

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
A first in human study to evaluate the safety, tolerability, and pharmacokinetics (PK) of BBO-8520, a KRAS G12C (ON) inhibitor, single agent and in combination with pembrolizumab in patients with advanced non-small cell lung cancer and colorectal cancer
Trial website
https://clinicaltrials.gov/study/NCT06343402
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
TheRas d/b/a BridgeBio Oncology Therapeutics
Address 0 0
Country 0 0
Phone 0 0
650-391-9740
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT06343402